Le Programme

De-escalation in genito-urinay cancers: The how, the why, the who! Prostate Cancer Bladder Cancer Testis Cancer

Tips and tricks for improving radical cystectomy outcomes Tips and tricks for improving TURBT Imaging versus TURBT in MIBC staging

Salvage strategies in the management of genito-urinary cancers Salvage Radiotherapy after radical prostatectomy: early salvage versus molecular imaging guided radiotherapy Salvage cystectomy following trimodal therapy

Peri-operative chemotherapy versus IO in invasive UTUC: chemotherapy versus IO IO duration in the management of mRCC: where are we in 2023?

Adjuvant treatments following nephrectomy: YES or NO mRCC: From standard first line to future strategies

Retzius sparing versus transperitoneal radical prostatectomy Focal Therapy in 2023: state of the art and perspectives

Which Surrogates in the management of prostate cancer? Localized prostate cancer Metastatic hormone sensitive prostate cancer Metastatic castration resistant prostate cancer

How to use PARPi in mCRPC patients in 2023! Best strategies with PARPi: sequential versus combo Is PARPi a good choice for all comers?

Implementation of biomarkers in daily practice How to use biomarkers from localized to castration resistant prostate cancer? How to use biomarkers from NMIBC to metastatic urothelial cancer?

Which second generation hormonal treatment to choose in mHSPC? A personalized approach Metachronous low volume mHSPC: intermitent, doublet or triplet therapy? Strategy to delay systemic treatments with SBRT in prostate... Read More

Metabolic imaging in GU cancers Future association between local and vectorized treatment in PCa Internal vectorized radiotherapy sequences in the management of metastatic prostate cancer

Specific clinical settings in the era of new treatments Management of metastatic non-clear cell kidney cancer Delayed nephrectomies: potential indications and outcomes

New challenges and opportunities in the management of genito-urinary cancers Treatment sequencing in the management of metastatic urothelial cancers Management of high-risk biochemical relapse after curative treatments for localized prostate... Read More

Micro ultrasound versus MRI fusion biopsies Active surveillance without biopsy: ready for prime time? YES versus NO

And FOCUS 2024 announcement